Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
26-week randomized open-label comparison of Generex Oral-lyn RapidMist versus injected human insulin in type 1 diabetes mellitus
2007-005899-13Phase 3Completed
- Sponsor
- Generex Biotechnology Corporation
- Start
- May 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Generex Oral-lyn in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Generex Biotechnology Corporation. Primary endpoint: Change in HbA1c from baseline to day 180. Started May 2008; status: completed.
02
Drugs
Generex Oral-lyn
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2007-005899-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005899-13.